NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

胞外體技術市場:產業分析·市場規模·佔有率·成長·趨勢·預測(2021年∼2031年)

Exosome Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

出版商 Transparency Market Research 商品編碼 1008612
出版日期 內容資訊 英文 301 Pages
商品交期: 最快1-2個工作天內
價格
胞外體技術市場:產業分析·市場規模·佔有率·成長·趨勢·預測(2021年∼2031年) Exosome Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031
出版日期: 2021年04月06日內容資訊: 英文 301 Pages
簡介

本報告提供全球胞外體技術市場調查,提供市場概要,胞外體類型·細胞起源·適應症·終端用戶·地區·各主要國家的成長率及市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,開發平台分析,新型冠狀病毒感染疾病(COVID-19)的影響分析,競爭情形,主要企業簡介等資訊。

目錄

第1章 序文

第2章 假設與調查手法

第3章 摘要整理

第4章 市場概要

  • 簡介
    • 類別定義
    • 產業的發展趨勢
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 市場分析與預測(實際成果值·預測值)

第5章 重要洞察

  • 新型冠狀病毒感染疾病(COVID-19)的短期·中期·長期的影響
  • 產業的主要趨勢(合併·收購·聯盟)
  • 開發平台分析
  • 技術發展
  • 授權契約

第6章 全球胞外體技術市場分析與預測:各胞外體類型

  • 簡介·定義
  • 主要調查結果·開發趨勢
  • 市場規模:各胞外體類型(實際成果值·預測值)
    • 貨物
    • 非貨物
  • 市場魅力分析:各胞外體類型

第7章 全球胞外體技術市場分析與預測:各細胞起源

  • 簡介·定義
  • 主要調查結果·開發趨勢
  • 市場規模:各細胞起源(實際成果值·預測值)
    • HEK293
    • MSC
    • 血小板
    • 紅血球
    • 自然殺手細胞(NK)
    • 其他
  • 市場魅力分析:各細胞起源

第8章 全球胞外體技術市場分析與預測:各適應症

  • 簡介·定義
  • 主要調查結果·開發趨勢
  • 市場規模:各適應症(實際成果值·預測值)
    • 治療
    • 診斷
  • 市場魅力分析:各適應症

第9章 全球胞外體技術市場分析與預測:各終端用戶

  • 簡介·定義
  • 主要調查結果·開發趨勢
  • 市場規模:各終端用戶(實際成果值·預測值)
    • 醫療提供者
    • 製藥·生物科技企業
    • 其他
  • 市場魅力分析:各終端用戶

第10章 全球胞外體技術市場分析與預測:各地區

  • 主要調查結果
  • 市場規模:各地區(預測值)
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析:各國和各地

第11章 北美的胞外體技術市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場規模:各胞外體類型(實際成果值·預測值)
    • 貨物
    • 非貨物
  • 市場規模:各細胞起源(實際成果值·預測值)
    • HEK293
    • MSC
    • 血小板
    • 紅血球
    • 自然殺手細胞(NK)
    • 其他
  • 市場規模:各適應症(實際成果值·預測值)
    • 治療
    • 診斷
  • 市場規模:各終端用戶(實際成果值·預測值)
    • 醫療提供者
    • 製藥·生物科技企業
    • 其他
  • 市場規模:各國(實際成果值·預測值)
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各胞外體類型
    • 各細胞起源
    • 各適應症
    • 各終端用戶
    • 各國

第12章 歐洲的胞外體技術市場分析與預測

第13章 亞太地區的胞外體技術市場分析與預測

第14章 南美的胞外體技術市場分析與預測

第15章 中東·非洲的胞外體技術市場分析與預測

第16章 競爭情形

  • 競爭矩陣(企業規模·各層級)
  • 市場佔有率分析:各企業(2020年)
  • 企業簡介
    • Aegle Therapeutics
    • Anjarium Biosciences
    • Aruna Biomedical
    • Carmine Therapeutics
    • Ciloa SAS
    • Codiak BioSciences
    • Creative Biolabs
    • Danaher Corporation(Beckman Coulter)
    • Direct Biologics
    • Evercyte
    • Evox Therapeutics
    • ExoCan Healthcare Technologies Pvt. Ltd.
    • ExoCoBio
    • ExonanoRNA LLC
    • Exopharm
    • Exosome Diagnostics, Inc.(BIO-TECHNE CORPORATION)
    • Fujifilm
    • ILIAS Biologics, Inc.
    • Illumina, Inc.
    • Invitrix Therapeutics
    • XOStem, Inc.
    • VivaZome Therapeutics Pty Ltd.
    • Thermo Fisher Scientific, Inc.
    • Organicell
    • OmniSpirant Ltd.
    • Novadip Biosciences
    • MDimune Inc.
    • Lonza
    • Kimera Labs
    • QIAGEN
    • Takara Bio, Inc.
    • Tavec Pharma
目錄
Product Code: TMRGL65840

Scope of the Report

TMR's report on the global exosome technologies market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global exosome technologies market for the period 2017-2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global exosome technologies market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global exosome technologies market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global exosome technologies market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global exosome technologies market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global exosome technologies market.

The report delves into the competitive landscape of the global exosome technologies market. Key players operating in the global exosome technologies market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global exosome technologies market that have been profiled in this report.

Key Questions Answered:

What is the revenue forecast for the global exosome technologies market in terms of revenue for the period 2021-2031?

  • How would various dynamics such as drivers, restraints, opportunities, and trends affect the market?
  • What is the market size and estimation for the exosome technologies market across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa?
  • Which regional market is poised to expand at a significant CAGR during the forecast period?
  • Which product segment is projected to generate considerable revenue in 2031 and which application segment will register the fastest CAGR during the forecast period?

Research Methodology

A unique methodology has been utilized by TMR to conduct a comprehensive research on the growth of the global exosome technologies market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary research sources referred to by analysts during the production of the global exosome technologies market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the exosome technologies market as primary methods.

These primary research respondents have provided exclusive information during interviews, which serves as a validation from the exosome technologies market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global exosome technologies market with accuracy. The study also uses the top-down approach to assess the revenue of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on future prospects of the global exosome technologies market more reliably and accurately.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Exosome Technologies Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Exosome Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Exosome Technologies Market Analysis and Forecast, 2015-2031

5. Key Insights

  • 5.1. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
  • 5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)
  • 5.3. Pipeline Analysis
  • 5.4. Technological Advancement
  • 5.5. Licensing deals (IP portfolio/patent/status of - Codiak, Ciloa SAS, Evox, and ExonanoRNA LLC)

6. Global Exosome Technologies Market Analysis and Forecast, by Exosome Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Exosome Type, 2015-2031
    • 6.3.1. Loaded Cargo
      • 6.3.1.1. Peptide
      • 6.3.1.2. siRNA
      • 6.3.1.3. mRNA
      • 6.3.1.4. miRNA
      • 6.3.1.5. Protein
      • 6.3.1.6. Chemical
      • 6.3.1.7. Others
    • 6.3.2. Non-cargo
  • 6.4. Market Attractiveness Analysis, by Exosome Type

7. Global Exosome Technologies Market Analysis and Forecast, by Cell Source

  • 7.1. Introduction & Definition
    • 7.1.1. Key Findings / Developments
  • 7.2. Market Value Forecast, by Cell Source, 2015-2031
    • 7.2.1. HEK293
    • 7.2.2. MSCs
    • 7.2.3. Platelets
    • 7.2.4. Erythrocytes
    • 7.2.5. Natural Killer Cells (NKs)
    • 7.2.6. Others
  • 7.3. Market Attractiveness Analysis, by Cell Source

8. Global Exosome Technologies Market Analysis and Forecast, by Indication

  • 8.1. Introduction & Definition
    • 8.1.1. Key Findings / Developments
  • 8.2. Market Value Forecast, by Indication, 2015-2031
    • 8.2.1. Therapeutics
      • 8.2.1.1. Oncology
      • 8.2.1.2. Neurodegenerative Diseases
      • 8.2.1.3. Cardiovascular Diseases
      • 8.2.1.4. Infectious Diseases
      • 8.2.1.5. Cosmetics
      • 8.2.1.6. Others
    • 8.2.2. Diagnostics
  • 8.3. Market Attractiveness Analysis, by Indication

9. Global Exosome Technologies Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
    • 9.1.1. Key Findings / Developments
  • 9.2. Market Value Forecast, by End-user, 2015-2031
    • 9.2.1. Health Care Providers
    • 9.2.2. Pharmaceutical & Biotechnology Companies
    • 9.2.3. Others
  • 9.3. Market Attractiveness Analysis, by End-user

10. Global Exosome Technologies Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Country/Region

11. North America Exosome Technologies Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Exosome Type, 2015-2031
    • 11.2.1. Loaded Cargo
      • 11.2.1.1. Peptide
      • 11.2.1.2. siRNA
      • 11.2.1.3. mRNA
      • 11.2.1.4. miRNA
      • 11.2.1.5. Protein
      • 11.2.1.6. Chemical
      • 11.2.1.7. Others
    • 11.2.2. Non-cargo
  • 11.3. Market Value Forecast, by Cell Source, 2015-2031
    • 11.3.1. HEK293
    • 11.3.2. MSCs
    • 11.3.3. Platelets
    • 11.3.4. Erythrocytes
    • 11.3.5. Natural Killer Cells (NKs)
    • 11.3.6. Others
  • 11.4. Market Value Forecast, by Indication, 2015-2031
    • 11.4.1. Therapeutics
      • 11.4.1.1. Oncology
      • 11.4.1.2. Neurodegenerative Diseases
      • 11.4.1.3. Cardiovascular Diseases
      • 11.4.1.4. Infectious Diseases
      • 11.4.1.5. Cosmetics
      • 11.4.1.6. Others
    • 11.4.2. Diagnostics
  • 11.5. Market Value Forecast, by End-user, 2015-2031
    • 11.5.1. Health Care Providers
    • 11.5.2. Pharmaceutical & Biotechnology Companies
    • 11.5.3. Others
  • 11.6. Market Value Forecast, by Country, 2015-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Exosome Type
    • 11.7.2. By Cell Source
    • 11.7.3. By Indication
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Exosome Technologies Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Exosome Type, 2015-2031
    • 12.2.1. Loaded Cargo
      • 12.2.1.1. Peptide
      • 12.2.1.2. siRNA
      • 12.2.1.3. mRNA
      • 12.2.1.4. miRNA
      • 12.2.1.5. Protein
      • 12.2.1.6. Chemical
      • 12.2.1.7. Others
    • 12.2.2. Non-cargo
  • 12.3. Market Value Forecast, by Cell Source, 2015-2031
    • 12.3.1. HEK293
    • 12.3.2. MSCs
    • 12.3.3. Platelets
    • 12.3.4. Erythrocytes
    • 12.3.5. Natural Killer Cells (NKs)
    • 12.3.6. Others
  • 12.4. Market Value Forecast, by Indication, 2015-2031
    • 12.4.1. Therapeutics
      • 12.4.1.1. Oncology
      • 12.4.1.2. Neurodegenerative Diseases
      • 12.4.1.3. Cardiovascular Diseases
      • 12.4.1.4. Infectious Diseases
      • 12.4.1.5. Cosmetics
      • 12.4.1.6. Others
    • 12.4.2. Diagnostics
  • 12.5. Market Value Forecast, by End-user, 2015-2031
    • 12.5.1. Health Care Providers
    • 12.5.2. Pharmaceutical & Biotechnology Companies
    • 12.5.3. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2015-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Exosome Type
    • 12.7.2. By Cell Source
    • 12.7.3. By Indication
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Exosome Technologies Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Exosome Type, 2015-2031
    • 13.2.1. Loaded Cargo
      • 13.2.1.1. Peptide
      • 13.2.1.2. siRNA
      • 13.2.1.3. mRNA
      • 13.2.1.4. miRNA
      • 13.2.1.5. Protein
      • 13.2.1.6. Chemical
      • 13.2.1.7. Others
    • 13.2.2. Non-cargo
  • 13.3. Market Value Forecast, by Cell Source, 2015-2031
    • 13.3.1. HEK293
    • 13.3.2. MSCs
    • 13.3.3. Platelets
    • 13.3.4. Erythrocytes
    • 13.3.5. Natural Killer Cells (NKs)
    • 13.3.6. Others
  • 13.4. Market Value Forecast, by Indication, 2015-2031
    • 13.4.1. Therapeutics
      • 13.4.1.1. Oncology
      • 13.4.1.2. Neurodegenerative Diseases
      • 13.4.1.3. Cardiovascular Diseases
      • 13.4.1.4. Infectious Diseases
      • 13.4.1.5. Cosmetics
      • 13.4.1.6. Others
    • 13.4.2. Diagnostics
  • 13.5. Market Value Forecast, by End-user, 2015-2031
    • 13.5.1. Health Care Providers
    • 13.5.2. Pharmaceutical & Biotechnology Companies
    • 13.5.3. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2015-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Exosome Type
    • 13.7.2. By Cell Source
    • 13.7.3. By Indication
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Exosome Technologies Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Exosome Type, 2015-2031
    • 14.2.1. Loaded Cargo
      • 14.2.1.1. Peptide
      • 14.2.1.2. siRNA
      • 14.2.1.3. mRNA
      • 14.2.1.4. miRNA
      • 14.2.1.5. Protein
      • 14.2.1.6. Chemical
      • 14.2.1.7. Others
    • 14.2.2. Non-cargo
  • 14.3. Market Value Forecast, by Cell Source, 2015-2031
    • 14.3.1. HEK293
    • 14.3.2. MSCs
    • 14.3.3. Platelets
    • 14.3.4. Erythrocytes
    • 14.3.5. Natural Killer Cells (NKs)
    • 14.3.6. Others
  • 14.4. Market Value Forecast, by Indication, 2015-2031
    • 14.4.1. Therapeutics
      • 14.4.1.1. Oncology
      • 14.4.1.2. Neurodegenerative Diseases
      • 14.4.1.3. Cardiovascular Diseases
      • 14.4.1.4. Infectious Diseases
      • 14.4.1.5. Cosmetics
      • 14.4.1.6. Others
    • 14.4.2. Diagnostics
  • 14.5. Market Value Forecast, by End-user, 2015-2031
    • 14.5.1. Health Care Providers
    • 14.5.2. Pharmaceutical & Biotechnology Companies
    • 14.5.3. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2015-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Exosome Type
    • 14.7.2. By Cell Source
    • 14.7.3. By Indication
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Exosome Technologies Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Exosome Type, 2015-2031
    • 15.2.1. Loaded Cargo
      • 15.2.1.1. Peptide
      • 15.2.1.2. siRNA
      • 15.2.1.3. mRNA
      • 15.2.1.4. miRNA
      • 15.2.1.5. Protein
      • 15.2.1.6. Chemical
      • 15.2.1.7. Others
    • 15.2.2. Non-cargo
  • 15.3. Market Value Forecast, by Cell Source, 2015-2031
    • 15.3.1. HEK293
    • 15.3.2. MSCs
    • 15.3.3. Platelets
    • 15.3.4. Erythrocytes
    • 15.3.5. Natural Killer Cells (NKs)
    • 15.3.6. Others
  • 15.4. Market Value Forecast, by Indication, 2015-2031
    • 15.4.1. Therapeutics
      • 15.4.1.1. Oncology
      • 15.4.1.2. Neurodegenerative Diseases
      • 15.4.1.3. Cardiovascular Diseases
      • 15.4.1.4. Infectious Diseases
      • 15.4.1.5. Cosmetics
      • 15.4.1.6. Others
    • 15.4.2. Diagnostics
  • 15.5. Market Value Forecast, by End-user, 2015-2031
    • 15.5.1. Health Care Providers
    • 15.5.2. Pharmaceutical & Biotechnology Companies
    • 15.5.3. Others
  • 15.6. Market Value Forecast, by Country/Sub-region, 2015-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Exosome Type
    • 15.7.2. By Cell Source
    • 15.7.3. By Indication
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis/Ranking, by Company, 2020
  • 16.3. Company Profiles
    • 16.3.1. Aegle Therapeutics
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Company Financials
      • 16.3.1.3. Growth Strategies
      • 16.3.1.4. SWOT Analysis
    • 16.3.2. Anjarium Biosciences
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Company Financials
      • 16.3.2.3. Growth Strategies
      • 16.3.2.4. SWOT Analysis
    • 16.3.3. Aruna Biomedical
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Company Financials
      • 16.3.3.3. Growth Strategies
      • 16.3.3.4. SWOT Analysis
    • 16.3.4. Carmine Therapeutics
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Company Financials
      • 16.3.4.3. Growth Strategies
      • 16.3.4.4. SWOT Analysis
    • 16.3.5. Ciloa SAS
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Company Financials
      • 16.3.5.3. Growth Strategies
      • 16.3.5.4. SWOT Analysis
    • 16.3.6. Codiak BioSciences
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Company Financials
      • 16.3.6.3. Growth Strategies
      • 16.3.6.4. SWOT Analysis
    • 16.3.7. Creative Biolabs
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Company Financials
      • 16.3.7.3. Growth Strategies
      • 16.3.7.4. SWOT Analysis
    • 16.3.8. Danaher Corporation (Beckman Coulter)
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Company Financials
      • 16.3.8.3. Growth Strategies
      • 16.3.8.4. SWOT Analysis
    • 16.3.9. Direct Biologics
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Company Financials
      • 16.3.9.3. Growth Strategies
      • 16.3.9.4. SWOT Analysis
    • 16.3.10. Evercyte
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Company Financials
      • 16.3.10.3. Growth Strategies
      • 16.3.10.4. SWOT Analysis
    • 16.3.11. Evox Therapeutics
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Company Financials
      • 16.3.11.3. Growth Strategies
      • 16.3.11.4. SWOT Analysis
    • 16.3.12. ExoCan Healthcare Technologies Pvt. Ltd.
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Company Financials
      • 16.3.12.3. Growth Strategies
      • 16.3.12.4. SWOT Analysis
    • 16.3.13. ExoCoBio
      • 16.3.13.1. Company Overview
      • 16.3.13.2. Company Financials
      • 16.3.13.3. Growth Strategies
      • 16.3.13.4. SWOT Analysis
    • 16.3.14. ExonanoRNA LLC
      • 16.3.14.1. Company Overview
      • 16.3.14.2. Company Financials
      • 16.3.14.3. Growth Strategies
      • 16.3.14.4. SWOT Analysis
    • 16.3.15. Exopharm
      • 16.3.15.1. Company Overview
      • 16.3.15.2. Company Financials
      • 16.3.15.3. Growth Strategies
      • 16.3.15.4. SWOT Analysis
    • 16.3.16. Exosome Diagnostics, Inc. (BIO-TECHNE CORPORATION)
      • 16.3.16.1. Company Overview
      • 16.3.16.2. Company Financials
      • 16.3.16.3. Growth Strategies
      • 16.3.16.4. SWOT Analysis
    • 16.3.17. Fujifilm
      • 16.3.17.1. Company Overview
      • 16.3.17.2. Company Financials
      • 16.3.17.3. Growth Strategies
      • 16.3.17.4. SWOT Analysis
    • 16.3.18. ILIAS Biologics, Inc.
      • 16.3.18.1. Company Overview
      • 16.3.18.2. Company Financials
      • 16.3.18.3. Growth Strategies
      • 16.3.18.4. SWOT Analysis
    • 16.3.19. Illumina, Inc.
      • 16.3.19.1. Company Overview
      • 16.3.19.2. Company Financials
      • 16.3.19.3. Growth Strategies
      • 16.3.19.4. SWOT Analysis
    • 16.3.20. Invitrix Therapeutics
      • 16.3.20.1. Company Overview
      • 16.3.20.2. Company Financials
      • 16.3.20.3. Growth Strategies
      • 16.3.20.4. SWOT Analysis
    • 16.3.21. XOStem, Inc.
      • 16.3.21.1. Company Overview
      • 16.3.21.2. Company Financials
      • 16.3.21.3. Growth Strategies
      • 16.3.21.4. SWOT Analysis
    • 16.3.22. VivaZome Therapeutics Pty Ltd.
      • 16.3.22.1. Company Overview
      • 16.3.22.2. Company Financials
      • 16.3.22.3. Growth Strategies
      • 16.3.22.4. SWOT Analysis
    • 16.3.23. Thermo Fisher Scientific, Inc.
      • 16.3.23.1. Company Overview
      • 16.3.23.2. Company Financials
      • 16.3.23.3. Growth Strategies
      • 16.3.23.4. SWOT Analysis
    • 16.3.24. Organicell
      • 16.3.24.1. Company Overview
      • 16.3.24.2. Company Financials
      • 16.3.24.3. Growth Strategies
      • 16.3.24.4. SWOT Analysis
    • 16.3.25. OmniSpirant Ltd.
      • 16.3.25.1. Company Overview
      • 16.3.25.2. Company Financials
      • 16.3.25.3. Growth Strategies
      • 16.3.25.4. SWOT Analysis
    • 16.3.26. Novadip Biosciences
      • 16.3.26.1. Company Overview
      • 16.3.26.2. Company Financials
      • 16.3.26.3. Growth Strategies
      • 16.3.26.4. SWOT Analysis
    • 16.3.27. MDimune Inc.
      • 16.3.27.1. Company Overview
      • 16.3.27.2. Company Financials
      • 16.3.27.3. Growth Strategies
      • 16.3.27.4. SWOT Analysis
    • 16.3.28. Lonza
      • 16.3.28.1. Company Overview
      • 16.3.28.2. Company Financials
      • 16.3.28.3. Growth Strategies
      • 16.3.28.4. SWOT Analysis
    • 16.3.29. Kimera Labs
      • 16.3.29.1. Company Overview
      • 16.3.29.2. Company Financials
      • 16.3.29.3. Growth Strategies
      • 16.3.29.4. SWOT Analysis
    • 16.3.30. QIAGEN
      • 16.3.30.1. Company Overview
      • 16.3.30.2. Company Financials
      • 16.3.30.3. Growth Strategies
      • 16.3.30.4. SWOT Analysis
    • 16.3.31. Takara Bio, Inc.
      • 16.3.31.1. Company Overview
      • 16.3.31.2. Company Financials
      • 16.3.31.3. Growth Strategies
      • 16.3.31.4. SWOT Analysis
    • 16.3.32. Tavec Pharma
      • 16.3.32.1. Company Overview
      • 16.3.32.2. Company Financials
      • 16.3.32.3. Growth Strategies
      • 16.3.32.4. SWOT Analysis

List of Tables

  • Table 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015-2031
  • Table 02: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015-2031
  • Table 03: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015-2031
  • Table 04: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015-2031
  • Table 05: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015-2031
  • Table 06: Global Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015-2031
  • Table 07: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Region, 2015-2031
  • Table 08: North America Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country, 2015-2031
  • Table 09: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015-2031
  • Table 10: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015-2031
  • Table 11: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015-2031
  • Table 12: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015-2031
  • Table 13: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015-2031
  • Table 14: North America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015-2031
  • Table 15: Europe Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015-2031
  • Table 16: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015-2031
  • Table 17: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015-2031
  • Table 18: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015-2031
  • Table 19: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015-2031
  • Table 20: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015-2031
  • Table 21: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015-2031
  • Table 22: Asia Pacific Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015-2031
  • Table 23: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015-2031
  • Table 24: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015-2031
  • Table 25: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015-2031
  • Table 26: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015-2031
  • Table 27: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015-2031
  • Table 28: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015-2031
  • Table 29: Latin America Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015-2031
  • Table 30: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015-2031
  • Table 31: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015-2031
  • Table 32: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015-2031
  • Table 33: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015-2031
  • Table 34: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015-2031
  • Table 35: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015-2031
  • Table 36: Middle East & Africa Exosome Technologies Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015-2031
  • Table 37: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2015-2031
  • Table 38: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargo, 2015-2031
  • Table 39: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2015-2031
  • Table 40: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Indication, 2015-2031
  • Table 41: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2015-2031
  • Table 42: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2015-2031

List of Figures

  • Figure 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, 2015-2031
  • Figure 02: Global Exosome Technologies Market Value Share, by Exosome Type, 2020
  • Figure 03: Global Exosome Technologies Market Value Share, by Cell Source, 2020
  • Figure 04: Global Exosome Technologies Market Value Share, by Indication, 2020
  • Figure 05: Global Exosome Technologies Market Value Share, by End-user, 2020
  • Figure 06: Global Exosome Technologies Market Value Share, by Region, 2020
  • Figure 07: Global Exosome Technologies Market Value Share Analysis, by Exosome Type, 2020 and 2031
  • Figure 08: Global Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021-2031
  • Figure 09: Global Exosome Technologies Market Revenue (US$ Mn), by Loaded Cargo, 2015-2031
  • Figure 10: Global Exosome Technologies Market Revenue (US$ Mn), by Non-cargo, 2015-2031
  • Figure 11: Global Exosome Technologies Market Value Share Analysis, by Cell Source, 2020 and 2031
  • Figure 12: Global Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021-2031
  • Figure 13: Global Exosome Technologies Market Revenue (US$ Mn), by HEK293, 2015-2031
  • Figure 14: Global Exosome Technologies Market Revenue (US$ Mn), by MSCs, 2015-2031
  • Figure 15: Global Exosome Technologies Market Revenue (US$ Mn), by Platelets, 2015-2031
  • Figure 16: Global Exosome Technologies Market Revenue (US$ Mn), by Erythrocytes, 2015-2031
  • Figure 17: Global Exosome Technologies Market Revenue (US$ Mn), by Natural Killer Cells (NKs), 2015-2031
  • Figure 18: Global Exosome Technologies Market Revenue (US$ Mn), by Others, 2015-2031
  • Figure 19: Global Exosome Technologies Market Value Share Analysis, by Indication, 2020 and 2031
  • Figure 20: Global Exosome Technologies Market Attractiveness Analysis, by Indication, 2021-2031
  • Figure 21: Global Exosome Technologies Market Revenue (US$ Mn), by Therapeutics, 2015-2031
  • Figure 22: Global Exosome Technologies Market Revenue (US$ Mn), by Diagnostics, 2015-2031
  • Figure 23: Global Exosome Technologies Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 24: Global Exosome Technologies Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 25: Global Exosome Technologies Market Revenue (US$ Mn), by Health Care Providers, 2015-2031
  • Figure 26: Global Exosome Technologies Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2015-2031
  • Figure 27: Global Exosome Technologies Market Revenue (US$ Mn), by Others, 2015-2031
  • Figure 28: Global Exosome Technologies Market Value Share Analysis, by Region, 2020 and 2031
  • Figure 29: Global Exosome Technologies Market Attractiveness Analysis, by Region, 2021-2031
  • Figure 30: North America Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (percentage) Projection, 2015-2031
  • Figure 31: North America Exosome Technologies Market Value Share (%), by Country, 2020 and 2031
  • Figure 32: North America Exosome Technologies Market Attractiveness Analysis, by Country, 2021-2031
  • Figure 33: North America Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031
  • Figure 34: North America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021-2031
  • Figure 35: North America Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031
  • Figure 36: North America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021-2031
  • Figure 37: North America Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031
  • Figure 38: North America Exosome Technologies Market Attractiveness Analysis, by Indication, 2021-2031
  • Figure 39: North America Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031
  • Figure 40: North America Exosome Technologies Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 41: Europe Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2031
  • Figure 42: Europe Exosome Technologies Market Value Share (%), by Country/Sub-region, 2020 and 2031
  • Figure 43: Europe Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 44: Europe Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031
  • Figure 45: Europe Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021-2031
  • Figure 46: Europe Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031
  • Figure 47: Europe Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021-2031
  • Figure 48: Europe Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031
  • Figure 49: Europe Exosome Technologies Market Attractiveness Analysis, by Indication, 2021-2031
  • Figure 50: Europe Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031
  • Figure 51: Europe Exosome Technologies Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 52: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2031
  • Figure 53: Asia Pacific Exosome Technologies Market Value Share (%), by Country/Sub-region, 2020 and 2031
  • Figure 54: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 55: Asia Pacific Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031
  • Figure 56: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021-2031
  • Figure 57: Asia Pacific Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031
  • Figure 58: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021-2031
  • Figure 59: Asia Pacific Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031
  • Figure 60: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Indication, 2021-2031
  • Figure 61: Asia Pacific Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031
  • Figure 62: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 63: Latin America Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2031
  • Figure 64: Latin America Exosome Technologies Market Value Share (%), by Country/Sub-region, 2020 and 2031
  • Figure 65: Latin America Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 66: Latin America Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031
  • Figure 67: Latin America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021-2031
  • Figure 68: Latin America Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031
  • Figure 69: Latin America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021-2031
  • Figure 70: Latin America Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031
  • Figure 71: Latin America Exosome Technologies Market Attractiveness Analysis, by Indication, 2021-2031
  • Figure 72: Latin America Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031
  • Figure 73: Latin America Exosome Technologies Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 74: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2031
  • Figure 75: Middle East & Africa Exosome Technologies Market Value Share (%), by Country/Sub-region, 2020 and 2031
  • Figure 76: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 77: Middle East & Africa Exosome Technologies Market Value Share (%), by Exosome Type, 2020 and 2031
  • Figure 78: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2021-2031
  • Figure 79: Middle East & Africa Exosome Technologies Market Value Share (%), by Cell Source, 2020 and 2031
  • Figure 80: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2021-2031
  • Figure 81: Middle East & Africa Exosome Technologies Market Value Share (%), by Indication, 2020 and 2031
  • Figure 82: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Indication, 2021-2031
  • Figure 83: Middle East & Africa Exosome Technologies Market Value Share (%), by End-user, 2020 and 2031
  • Figure 84: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by End-user, 2021-2031